Kinase Inhibitors in Cancer and Central Nervous System

Dear Colleagues,

Protein kinases catalyse protein phosphorylation—a key cellular regulatory mechanism which is frequently dysregulated in human diseases. Kinases have consequently been linked to the progress of a variety of diseases, including cancer and neurodegenerative disorders. Therefore, the search for therapeutic inhibitors of specific kinases has been developed in the last three decades as a major approach to discovering new therapeutic drugs. Initially focused on the discovery, optimization, and characterization of tyrosine kinase inhibitors and on cancer indications, the field is now rapidly expanding towards serine/threonine kinases and essentially all other therapeutic indications as neurodegenerative diseases (Alzheimer’s disease, Down syndrome).

In this Special Issue, our goal is to highlight papers describing an intended inhibition of specific kinases, although they are not always the initial and main target of the compounds tested. In silico molecular design connected with the development of chemical syntheses and pertinent comments on the forthcoming applications of these inhibitors will be particularly appreciated.

Prof. Dr. Thierry Besson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Scientia Pharmaceutica is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Alzheimer’s disease
• neurodegenerative diseases
• Down syndrome
• cancer
• kinase inhibitors
• in silico design
• multi-target drug ligand
• cancer cell quiescence
• chemical synthesis
• tyrosine kinases
• Ser/Thr kinases
• dual-specificity tyrosine phosphorylation-regulated kinases